Linadus M 2.5/500 mg Tablet

About Linadus M 2.5/500 mg Tablet

Linadus M 2.5/500 mg 2.5 mg + 500 mg tablet is a medicine made by Opsonin Pharma Limited. It is not a replacement for healthy eating and physical activity.

There are 31 brands of Linagliptin + Metformin Hydrochloride listed in Bangladesh. The lowest listed price is Linatin M 2.5 mg + 500 mg Tablet at ৳ 7.00 per unit.

What is Linadus M 2.5/500 mg Tablet?

Linadus M 2.5/500 mg 2.5 mg + 500 mg is a tablet product of Opsonin Pharma Limited that contains Linagliptin + Metformin Hydrochloride. Linagliptin works by increasing certain gut hormones that help release insulin when blood sugar is high. Only a registered doctor can decide whether it suits a particular person, and the dose and course are set by the doctor. The doctor decides the dose and course for each person.

Uses of Linadus M 2.5/500 mg

It is not a replacement for healthy eating and physical activity. It is given together with diet and exercise to help improve blood sugar control when a doctor judges that treatment with both linagliptin and metformin hydrochloride is appropriate. Your doctor will decide if it is suitable for you.

How to use Linadus M 2.5/500 mg

Swallow it as advised by your doctor or pharmacist. Swallow the tablet with water. Linadus M 2.5/500 mg is taken by mouth. Take Linadus M 2.5/500 mg exactly as prescribed by your doctor. If you miss a dose or are unsure how to take it, ask your doctor or pharmacist rather than guessing. The dose and course are decided by the doctor, who adjusts them to your needs and tolerance.

Side effects of Linadus M 2.5/500 mg

Some people may have other reactions. Ask the doctor or pharmacist what warning signs to watch for and when to seek help, and report any side effect that worries you or does not settle. If you notice any unusual symptoms or feel unwell while taking it, contact your doctor. Tell your doctor if any side effect bothers you or does not go away.

Safety and precautions

It is also not for people with acute or chronic metabolic acidosis such as diabetic ketoacidosis, or those allergic to linagliptin or metformin. Your doctor may stop the medicine around surgery or certain imaging tests, and will decide what is right for you. Metformin is excreted by the kidneys, so the risk of accumulation and lactic acidosis rises as kidney function falls. Tell your doctor about kidney problems, surgery, contrast imaging or other medicines first.

Frequently asked questions

What is Linadus M 2.5/500 mg used for?

It is not a replacement for healthy eating and physical activity. It is given together with diet and exercise to help improve blood sugar control when a doctor judges that treatment with both linagliptin and metformin hydrochloride is appropriate.

How is Linadus M 2.5/500 mg used?

Swallow it as advised by your doctor or pharmacist. Swallow the tablet with water.

What are the side effects of Linadus M 2.5/500 mg?

Some people may have other reactions. Ask the doctor or pharmacist what warning signs to watch for and when to seek help, and report any side effect that worries you or does not settle.

Can I use Linadus M 2.5/500 mg in pregnancy or while breastfeeding?

It is also not for people with acute or chronic metabolic acidosis such as diabetic ketoacidosis, or those allergic to linagliptin or metformin. Your doctor may stop the medicine around surgery or certain imaging tests, and will decide what is right for you.

Indications

This is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both Linagliptin and Metformin Hydrochloride is appropriate

Pharmacology

Linagliptin is indicated to improve glycemic control in patients with type 2 diabetes mellitus. Linagliptin is an inhibitor of DPP-4 (dipeptidyl peptidase-4), an enzyme that degrades the incretin hormones GLP-1 (glucagon like peptide-1) and GIP (glucose dependent insulinotropic polypeptide). Thus, Linagliptin increases the concentrations of active incretin hormones, stimulating the release of insulin from pancreatic beta (β) cells in a glucose-dependent manner and decreasing the secretion of glucagon from pancreatic alpha (α) cells in the circulation.

Metformin Hydrochloride is a biguanide type oral antihyperglycemic drug used in the management of type 2 diabetes. It lowers both basal and postprandial plasma glucose. Its mechanism of action is different from those of sulfonylureas and it does not produce hypoglycemia. Metformin Hydrochloride decreases hepatic glucose production, decreases intestinal absorption of glucose and improves insulin sensitivity by an increase in peripheral glucose uptake and utilization.

Dosage & Administration

Linagliptin & Metformin immediate release tablet: The dosage of Linagliptin & Metformin should be individualized on the basis of both effectiveness and tolerability. Maximum recommended dose of 2.5 mg Linagliptin and 1000 mg Metformin Hydrochloride twice daily with meals. Dose escalation should be gradual to reduce the gastrointestinal (GI) side effects associated with Metformin Hydrochloride use.

Recommended starting dose: In patients currently not treated with Metformin Hydrochloride, initiate treatment with 2.5 mg Linagliptin and 500 mg Metformin Hydrochloride twice daily.

In patients already treated with Metformin Hydrochloride, start with 2.5 mg Linagliptin and the current dose of Metformin Hydrochloride twice daily.

Patients already treated with Linagliptin and Metformin Hydrochloride, individual components may be switched to this combination containing the same doses of each component.

Linagliptin & Metformin extend release tablet: The dosage of this combination should be individualized on the basis of both effectiveness and tolerability, while not exceeding the maximum recommended total daily dose of Linagliptin 5 mg and Metformin Hydrochloride 2000 mg. this combination should be given once daily with a meal.

Recommended starting dose: In patients currently not treated with metformin, initiate this combination treatment with 5 mg Linagliptin/1000 mg Metformin Hydrochloride extended-release once daily with a meal.

In patients already treated with Metformin, start this combination with 5 mg of Linagliptin total daily dose and a similar total daily dose of Metformin once daily with a meal.

In patients already treated with Linagliptin & Metformin immediate release tablet, switch to extend release tablet containing 5 mg of Linagliptin total daily dose and a similar total daily dose of Metformin once daily with a meal.

5 mg Linagliptin & 1000 mg Metformin Hydrochloride extended-release tablet should be taken as a single tablet once daily. Patients using 2.5 mg Linagliptin & 1000 mg Metformin extended release tablets should take two tablets together once daily.

Interaction

Cationic drugs (amiloride, digoxin, morphine, ranitidine, trimethoprim etc.): May reduce metformin elimination.

P-glycoprotien/CYP3A4 inducer (i.e. rifampin)
: The efficacy of this medicine may be reduced when administered in combination.

Contraindications

Although Linagliptin undergoes minimal renal excretion, Metformin Hydrochloride is known to be substantially excreted by the kidney. The risk of Metformin Hydrochloride accumulation and lactic acidosis increases with the degree of renal impairment. Therefore, this combination is contraindicated in patients with renal impairment. It is also contraindicated in acute or chronic metabolic acidosis (diabetic ketoacidosis) and in hypersensitivity to Linagliptin or Metformin Hydrochloride.

Side Effects

Most common side effects are nasopharyngitis and diarrhea. Hypoglycemia is more common in patients treated with this combination and sulfonylureas.

Pregnancy & Lactation

There are no adequate and well-controlled studies in pregnant women with this combination or its individual component; so it should be used during pregnancy only if clearly needed. Caution should also be excercised when it is administered to a lactating mother.

Precautions & Warnings

In a patient with lactic acidosis who is taking Metformin, the drug should be discontinued immediately and supportive therapy promptly instituted. There have been postmarketing reports of acute pancreatitis. If pancreatitis is suspected, promptly discontinue Linagliptin & Metformin. Temporarily discontinue Linagliptin & Metformin in patients undergoing radiologic studies with intravascular administration of iodinated contrast materials or any surgical procedures necessitating restricted intake of food and fluids. Metformin may lower Vitamin B12 levels; so hematologic parameters shoud be monitored annually.

Overdose Effects

In the event of an overdose with this combination the usual supportive measures (i.e. remove unabsorbed material from the gastrointestinal tract, perform clinical monitoring, and institute supportive treatment) should be employed. Removal of Linagliptin by hemodialysis or peritoneal dialysis is unlikely but Metformin Hydrochloride is dialyzable.

During controlled clinical trials in healthy subjects, with single doses of up to 600 mg of Linagliptin (equivalent to 120 times the recommended daily dose), there were no dose-related clinical adverse drug reactions.

Overdose of Metformin Hydrochloride has occurred in case of ingestion of amounts greater than 50 grams. Hypoglycemia was reported in approximately 10% of cases, but no causal association with Metformin Hydrochloride has been established. Lactic acidosis has been reported in approximately 32% of Metformin Hydrochloride overdose cases.

Storage Conditions

Keep in a cool & dry place (below 30°C), protected from light & moisture. Keep out of the reach of children.

Alternative brands of Linagliptin + Metformin Hydrochloride

Other brands with the same generic name, cheapest first.

See all 31 brands

Medicine information is for reference only and is not medical advice. Always follow your doctor's prescription and check with a pharmacist.